Pirfenidone + BI 1015550 for Idiopathic Pulmonary Fibrosis

This trial tests the interaction of two medicines, pirfenidone and BI 1015550 (a new potential drug), in individuals with idiopathic pulmonary fibrosis (IPF), a lung disease that makes breathing difficult. Participants will take these medications in a specific order to determine if one affects the blood levels of the other. The study aims to ensure the medicines work well together without causing unwanted effects. The trial seeks adults with IPF who are eligible for pirfenidone treatment. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important advancements in IPF treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Research has shown that BI 1015550 is generally safe for people with idiopathic pulmonary fibrosis (IPF). One study found it safe for both healthy individuals and those with IPF, indicating that most participants tolerated the treatment well.

Pirfenidone, a treatment already used for IPF, has a well-established safety record. Studies indicate it effectively slows the disease's progression. While some side effects may occur, they are usually manageable with a doctor's assistance.

Most treatments for idiopathic pulmonary fibrosis, like nintedanib and pirfenidone, aim to slow down lung damage by inhibiting pathways that lead to fibrosis. However, researchers are excited about BI 1015550 because it introduces a novel mechanism, acting as a PDE4B inhibitor. This action potentially addresses inflammation and fibrosis more directly. When combined with pirfenidone, this dual approach might enhance the overall effectiveness, offering a promising new angle to tackle the progression of this challenging condition.

Previous studies have shown that BI 1015550 holds promise for treating idiopathic pulmonary fibrosis (IPF) by preventing lung deterioration. It blocks a specific enzyme, potentially slowing the disease. Research has also found that another medicine, Pirfenidone, slows the disease in IPF patients, reducing the risk of lung function decline and improving overall survival chances. In this trial, participants will initially receive BI 1015550, followed by a combination of Pirfenidone and BI 1015550. Both medicines have proven effective in managing IPF symptoms and slowing the disease's progression.⁴⁵⁶⁷⁸